Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2995171

O=C(O)C(F)(F)F.O=C1N=C(Nc2c(Cl)cccc2Cl)SC1=Cc1ccc2nccc(N3CCCCC3)c2c1

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CISD1 Q9NZ45 1/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 2/20 0.35
EGFR P00533 2/20 0.35
KDM4E B2RXH2 1/20 0.34
CHKA P35790 1/20 0.34
RAB9A P51151 1/20 0.34
ENPP2 Q13822 2/20 0.34
HTR6 P50406 1/20 0.34
PDGFRB P09619 1/20 0.34
PIK3CA P42336 1/20 0.34
DYRK3 O43781 1/20 0.33
CSNK1E P49674 1/20 0.33
CLK1 P49759 1/20 0.33
CLK2 P49760 1/20 0.33
CLK3 P49761 1/20 0.33
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4586308 1.00 CISD1 (0.36) CISD1KMT2AALDH1A1MAPTHTT
Trifluoroacetic Acid SCHEMBL2995167 1.00 CISD1 (0.36) CISD1KMT2AALDH1A1MAPTHTT
SCHEMBL4586474 0.93 KMT2A (0.41) KMT2AALDH1A1MAPTHTTMEN1
SCHEMBL4586479 0.93 KMT2A (0.41) KMT2AALDH1A1MAPTHTTMEN1
SCHEMBL2995679 0.92 KMT2A (0.41) KMT2AALDH1A1MAPTHTTMEN1
SCHEMBL4585273 0.92 KMT2A (0.41) KMT2AALDH1A1MAPTHTTMEN1
SCHEMBL2995682 0.92 KMT2A (0.41) KMT2AALDH1A1MAPTHTTMEN1
SCHEMBL2996092 0.85 ENPP2 (0.48) CISD1KDM4EENPP2HTR6PIK3CA
SCHEMBL2993546 0.85 MEN1 (0.40) CISD1KMT2AALDH1A1MAPTHTT
SCHEMBL2993532 0.85 HTR6 (0.47) HTR6PIK3CADYRK3CSNK1ECLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214455-A1 Novel Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-04 US claimed
EP-1879563-A4 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-07-16 EP claimed
EP-1879563-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-01-23 EP claimed
WO-2006132739-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO claimed
US-20100184774-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION 2010-07-22 US disclosed
EP-2164494-A1 METHODS OF TREATMENT GlaxoSmithKline LLC (US) 2010-03-24 EP disclosed
WO-2008150837-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080214455-A1 Novel Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-04 US disclosed
EP-1879563-A4 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-07-16 EP disclosed
EP-1879563-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-01-23 EP disclosed
WO-2006132739-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214455-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 CISD1 3112/4885KMT2A 3294/4885ALDH1A1 4089/4885
US-20100184774-A1 METHODS OF TREATMENT OPRL1, BRCA1, PKD1 CISD1 3370/4885KMT2A 2272/4885ALDH1A1 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.